A novel selectively targeting gene delivery approach has been developed for advanced hepatocellular carcinoma (HCC), a leading cause of cancer mortality whose prognosis remains poor. We combine the strong liver tropism of serotype-8 capsid-pseudotyped adeno-associated viral vectors (AAV8) with a liver-specific promoter (HLP) and microRNA-122a (miR-122a)-mediated posttranscriptional regulation. Systemic administration of our AAV8 construct resulted in preferential transduction of the liver and encouragingly of HCC at heterotopic sites, a finding that could be exploited to target disseminated disease. Tumor selectivity was enhanced by inclusion of miR-122a-binding sequences (ssAAV8-HLP-TK-122aT4) in the expression cassette, resulting in abrogation of transgene expression in normal murine liver but not in HCC. Systemic administration of our tumor-selective vector encoding herpes simplex virus-thymidine kinase (TK) suicide gene resulted in a sevenfold reduction in HCC growth in a syngeneic murine model without toxicity. In summary, we have developed a systemically deliverable gene transfer approach that enables high-level expression of therapeutic genes in HCC but not normal tissues, thus improving the prospects of safe and effective treatment for advanced HCC.
Get full access to this article
View all access options for this article.
References
1.
JemalA, BrayF, CenterMM, et al.Global cancer statistics. CA Cancer J Clin, 2011; 61:69–90.
2.
WilhelmSM, AdnaneL, NewellP, et al.Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther, 2008; 7:3129–3140.
3.
BoniniC, FerrariG, VerzelettiS, et al.HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science, 1997; 276:1719–1724.
4.
DranoffG, SoifferR, LynchT, et al.A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther, 1997; 8:111–123.
5.
Lupo-StanghelliniMT, ProvasiE, BondanzaA, et al.Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum Gene Ther, 2010; 21:241–250.
6.
OkadaT, ShahM, HigginbothamJN, et al.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits. Gene Ther, 2001; 8:1315–1322.
7.
PorterDL, LevineBL, KalosM, et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med, 2011; 365:725–733.
8.
RosenbergSA, YangJC, SherryRM, et al.Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res, 2011; 17:4550–4557.
9.
NathwaniAC, GrayJT, McIntoshJ, et al.Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood, 2007; 109:1414–1421.
10.
NathwaniAC, RosalesC, McIntoshJ, et al.Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther, 2011; 19:876–885.
11.
NathwaniAC, TuddenhamEG, RangarajanS, et al.Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med, 2011; 365:2357–2365.
12.
CoulouarnC, FactorVM, AndersenJB, et al.Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene, 2009; 28:3526–3536.
13.
FuX, RiveraA, TaoL, et al.Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells. Mol Ther, 2012; 20:339–346.
14.
KutayH, BaiS, DattaJ, et al.Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem, 2006; 99:671–678.
15.
Lagos-QuintanaM, RauhutR, YalcinA, et al.Identification of tissue-specific microRNAs from mouse. Curr Biol, 2002; 12:735–739.
16.
MurakamiY, YasudaT, SaigoK, et al.Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene, 2006; 25:2537–2545.
17.
TsaiWC, HsuPW, LaiTC, et al.MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology, 2009; 49:1571–1582.
18.
TsaiWC, HsuSD, HsuCS, et al.MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest, 2012; 122:2884–2897.
19.
AllayJA, SleepS, LongS, et al.Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther, 2011; 22:595–604.
20.
YanR, SanderK, GalanteE, et al.A one-pot three-component radiochemical reaction for rapid assembly of 125I-labeled molecular probes. J Am Chem Soc, 2013; 135:703–709.
21.
McIntoshJ, LentingPJ, RosalesC, et al.Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood, 2013; 121:3335–3344.
22.
SuzukiT, SakuraiF, NakamuraS, et al.miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol Ther, 2008; 16:1719–1726.
23.
HeffelfingerSC, HawkinsHH, BarrishJ, et al.SK HEP-1: a human cell line of endothelial origin. In Vitro Cell Dev Biol, 1992; 28A:136–142.
24.
HerraezE, LozanoE, MaciasRI, et al.Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology, 2013; 58:1065–1073.
25.
LinLI, KeYF, KoYC, et al.Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Oncology, 1998; 55:349–353.
26.
ChangJ, NicolasE, MarksD, et al.miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol, 2004; 1:106–113.
27.
NathwaniAC, GrayJT, NgCY, et al.Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 2006; 107:2653–2661.
28.
PanedaA, CollantesM, BeattieSG, et al.Adeno-associated virus liver transduction efficiency measured by in vivo [18F]FHBG positron emission tomography imaging in rodents and nonhuman primates. Hum Gene Ther, 2011; 22:999–1009.
29.
Hernandez-AlcocebaR, SangroB, PrietoJ. Gene therapy of liver cancer. World J Gastroenterol, 2006; 12:6085–6097.
30.
OzakiI, YamamotoK, MizutaT, et al.Differential expression of laminin receptors in human hepatocellular carcinoma. Gut, 1998; 43:837–842.
31.
European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 2012; 56:908–943.
32.
HanDH, ChoiGH, KimKS, et al.Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiation. J Gastroenterol Hepatol, 2013; 28:1384–1390.
33.
OishiK, ItamotoT, AmanoH, et al.Clinicopathologic features of poorly differentiated hepatocellular carcinoma. J Surg Oncol, 2007; 95:311–316.
34.
WaidmannO, KoberleV, BrunnerF, et al.Serum microRNA-122 predicts survival in patients with liver cirrhosis. PLoS One, 2012; 7:e45652.
35.
KoberleV, KronenbergerB, PleliT, et al.Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer, 2013; 49:3442–3449.
DonsanteA, VoglerC, MuzyczkaN, et al.Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther, 2001; 8:1343–1346.
38.
KayMA. AAV vectors and tumorigenicity. Nat Biotechnol, 2007; 25:1111–1113.
39.
MillerDG, TrobridgeGD, PetekLM, et al.Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol, 2005; 79:11434–11442.
40.
NakaiH, WuX, FuessS, et al.Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol, 2005; 79:3606–3614.
41.
NakaiH, YantSR, StormTA, et al.Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol, 2001; 75:6969–6976.
42.
DonsanteA, MillerDG, LiY, et al.AAV vector integration sites in mouse hepatocellular carcinoma. Science, 2007; 317:477.
43.
BellP, MoscioniAD, McCarterRJ, et al.Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther, 2006; 14:34–44.
44.
LeberMF, BossowS, LeonardVH, et al.MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol Ther, 2011; 19:1097–1106.
45.
LeeCY, RenniePS, JiaWW. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res, 2009; 15:5126–5135.
46.
QiaoC, YuanZ, LiJ, et al.Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther, 2011; 18:403–410.
47.
HeoJ, ReidT, RuoL, et al.Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med, 2013; 19:329–336.
48.
QianC, IdoateM, BilbaoR, et al.Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Hum Gene Ther, 1997; 8:349–358.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
